Ascend Biopharmaceuticals clinical trial program update

September 04, 2014: Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has released an update on the clinical trial pipeline for its lead immunotherapy products treating basal cell carcinoma (BCC) and breast cancer.

Press Release: Clinical Trial Program Update


Download Corporate Presentation


About Ascend

Ascend is a cancer immunology company developing medicines to treat primary, recurrent and metastatic cancers. Cancers are made up of many different cell types and a number of these can regulate the local tumour microenvironment to promote tumour growth.

Ascend's strategy focuses on targeting these key cells and to alter the local microenvironment and host response from one that endows tumour growth to one that causes cancer eradication.